Ginkgo Bioworks (DNA) Q1 Revenues Beat; Guides Higher
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/3/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Equities close higher as softer jobs data quiets rate-hike expectations
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- Tanker struck by projectile in Strait of Hormuz
- AppLovin shares fall after court denies request against Unity
Ginkgo Bioworks Reports First Quarter 2022 Financial Results
May 16, 2022 4:01 PM EDT$168 million of Total revenue in Q1 2022, representing an increase of 282% over Q1 2021
11 new Cell Programs added in Q1 2022, representing 175% growth over Q1 2021
Increasing full year guidance for Total revenue from $325Â $340 million to $375 $390 million, reiterating Foundry revenue guidance and increasing Biosecurity revenue guidance
Recently announced plans to expand platform capabilities in agricultural biologicals through a series of M&A transactions and flagship collaboration with Bayer
$1.5 billion cash balance provides meaningful multi-year runway as we drive towards... More
